Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe.
Skin and soft-tissue infections (SSTIs) are a common indication for antibiotic use in Europe and are associated with considerable morbidity. Treatment of SSTIs, occasionally complicated by infection with meticillin-resistant Staphylococcus aureus, can be resource intensive and lead to high healthcare costs. For patients treated in an inpatient setting, once the acute infection has been controlled, a patient may be discharged on suitable oral antibiotic therapy or outpatient parenteral antibiotic therapy. The recently confirmed efficacy of single-dose (e.g. oritavancin) and two-dose (e.g. dalbavancin) infusion therapies as well as tedizolid phosphate, a short-duration therapy available both for intravenous (i.v.) and oral use, for treating SSTIs has highlighted the need for clinicians to re-evaluate their current treatment paradigms. In addition, recent clinical trial data reporting a novel endpoint of early clinical response, defined as change in lesion size at 48-72 h, may be of value in determining which patients are most suitable for early de-escalation of therapy, including switch from i.v. to oral antibiotics, and subsequent early hospital discharge. The aim of this paper is to review the potential impact of assessing clinical response on clinical decision-making in the management of SSTIs in Europe, with a focus on emerging therapies.
Ninewells Hospital and Medical School, Ward 42, East Block, Dundee DD1 9SY, UK. Electronic address: dilip.nathwani@nhs.net.
Dilip
D
Nathwani
Royal Hampshire County Hospital, Romsey Road, Winchester SO22 5DG, UK.
Matthew
M
Dryden
Hospital Universitari Mutúa de Terrassa, Plaza Dr Robert 5, Barcelona 08221, Spain.
Javier
J
Garau
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D016903:Drug Monitoring; D005060:Europe; D006801:Humans; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D018461:Soft Tissue Infections / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents
Antibiotic treatment; Clinical assessment; Early discharge; Skin and soft-tissue infection